{"id":"W2346455687","doi":"10.6000/1927-7229.2015.04.03.1","title":"Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors","year":2015,"lang":"en","type":"article","venue":"Journal of Analytical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; Lung cancer; Epidermal growth factor receptor; Progression-free survival; Performance status; Erlotinib Hydrochloride; Cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001476539,0.0001303883,0.0004984328,0.000103334,0.00003907998,0.00001009374,0.0000545496,0.00007903874,0.00009831106],"category_scores_gemma":[0.00007780764,0.00007925033,0.00007481186,0.0001328943,0.00006695503,0.00008734498,0.00001139012,0.000175934,0.000001888656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00034747,"about_ca_system_score_gemma":0.001484884,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001715595,"about_ca_topic_score_gemma":0.00002789095,"domain_scores_codex":[0.9991012,0.0000204615,0.000358062,0.0001432158,0.0001773659,0.0001997565],"domain_scores_gemma":[0.9983013,0.0001285157,0.0002836797,0.00008769966,0.0008345437,0.0003642797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04219949,0.007518915,0.8310601,0.0003075367,0.004343595,0.0006035265,0.003644827,0.0006988483,0.0005100296,0.0004206549,0.02544717,0.08324532],"study_design_scores_gemma":[0.1914072,0.201321,0.306725,0.0007258237,0.007240774,0.0006062781,0.002164336,0.005051215,0.00133404,0.0007577088,0.2818554,0.0008112526],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931059,0.0009936414,0.0001757623,0.002547629,0.0002412232,0.0005192224,0.00001043478,0.000005209825,0.002400906],"genre_scores_gemma":[0.9920292,0.0002723708,0.003964962,0.001586107,0.0002687298,0.00001620339,0.00001284253,0.00002347731,0.001826057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5243351,"threshold_uncertainty_score":0.3231734,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02052507521711275,"score_gpt":0.3760198581670536,"score_spread":0.3554947829499409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}